This interview from Practice Update with Dr Neeraj Agarwal from the Hunstman Cancer Center, Salt Lake City, Utah, USA discusses current and potential biomarkers for renal cell carcinoma (RCC).

The two most common models currently used in the clinic are the Memorial Sloan-Kettering (MSKCC) model and the International Metastatic Renal Cell Carcinoma Consortium (IMDC) model, the latter being used more widely in clinics and clinical trials, and which categorises patients according to disease risk, such as favourable, intermediate or poor. The interview also covers genomic profiling to enhance these prognostic models, and the use of circulating tumour DNA (ctDNA) for genomic profiling.

Watch the video interview on Practice Update here